July 30^th, 2007 - Cambridge / Jerusalem - Antitope Ltd., inventors of the Composite Human Antibody^TM technology, announced a research and product development agreement with ProtAb Ltd. (a wholly-owned portfolio company of Hadasit Bio-Holdings Ltd, traded on the Tel Aviv Stock Exchange: HDST) for the generation of therapeutic antibodies.  Under the research agreement Antitope will generate a humanized monoclonal antibody for the treatment of rheumatoid arthritis and other autoimmune diseases.

"We are delighted to have been chosen by ProtAb in this exciting collaboration to produce therapeutic antibodies against ProtAb's proprietary targets" said Dr. Matthew Baker, Chief Scientific Officer and co-founder of Antitope Limited.  "This collaboration, using Antitope's extensive expertise in antibody humanization, will assist ProtAb in rapidly producing humanized antibodies for use in the clinic to treat patients with rheumatoid arthritis."

Mrs. Shira Yair, General Manager of ProtAb, commented on the transaction: "We feel that the collaboration with Antitope is a significant milestone on the way to commencement of a clinical trial with ProtAb's lead antibody. Antitope offers rich experience and unique and innovative know-how that has already led other companies to a successful and rapid conversion from the murine antibody form to a humanized version. We hope this interaction can lead to a wider collaboration with Antitope for both ProtAb and HBL in the future."

About Antitope:

Antitope Ltd. is a Cambridge UK-based biotechnology company specializing in immunogenicity testing and the engineering of therapeutic antibodies/proteins to reduce immunogenicity.  Antitope's proprietary Composite Human Antibody technology builds upon the previous pioneering work of its founders in the detection and removal of T cell epitopes in antibodies/proteins through humanization and DeImmunisation technologies.  Antitope is a privately-held company and has established multiple commercial relationships with leading biotechnology and pharmaceutical companies.  For further information on Antitope visit http://www.antitope.co.uk/.

About ProtAb:

ProtAb Ltd. is focused on the development of a unique and innovative therapeutic approach for the treatment of autoimmune inflammatory diseases based on a biologic drug that activates anti-inflammatory signaling pathways. The company's first product is an anti-HSP-epitope monoclonal antibody for the treatment of rheumatoid arthritis and other autoimmune diseases.  After exhibiting strong scientific evidence in animal models, ProtAb is advancing the development of its anti-HSP-epitope antibody towards clinical application.

ProtAb is based in Jerusalem, Israel, and is one of the nine portfolio companies of Hadasit Bio-Holdings Ltd. (HBL).

About Hadasit Bio-Holdings:

Hadasit Bio-Holdings Ltd. (TASE: HDST) was established by Hadasit (the technology transfer company of the Hadassah Medical Organization) in 2005 to capitalize on the knowledge and experience accumulated in its research laboratories. Hadasit Bio-Holdings currently owns nine biotechnology startups that have already demonstrated the feasibility and effectiveness of their products in animal models and are in preparation for clinical trials in human beings. The HBL companies have developed drugs with blockbuster market potential (annual markets exceeding one billion dollars) that are intended for the treatment of cancer, inflammatory diseases, and tissue regeneration using stem cells - areas in which Hadassah University Hospital has major expertise and an international reputation as a scientific, technological, and clinical leader. For additional information, please visit the Hadasit Bio-Holdings website: http://www.hbl.co.il/

For further information on Antitope contact:

Dr Neil Butt

Business Development Director

Tel: +44 (0)1223 496190

Email: neil.butt@antitope.co.uk

For further information on ProtAb, contact:

Mrs. Shira Yair

General Manager

Tel: 972-2-6778175

E-mail: shira@protab.co.il